New rad combo targets kidney cancer after immunotherapy fails

NCT ID NCT06255223

Recruiting now Disease control Sponsor: Jinling Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of high-dose and low-dose radiotherapy, plus an immunotherapy drug, in 35 people with kidney cancer that got worse after prior immunotherapy. The goal is to see if this approach can control the disease and how safe it is. Participants will be monitored for tumor response and side effects over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiotherapy (high-dose and low-dose) combined with an anti-PD-1 monoclonal antibody
What this could lead to: If successful, this could offer a new treatment option for kidney cancer patients whose disease worsened after immunotherapy, potentially helping to control tumor growth.
What could go wrong: This is a small, early-phase trial with only 35 participants, so results may not apply to all patients. Radiotherapy and immunotherapy can cause side effects, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT INHIBITOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE CHECKPOINT INHIBITOR RADIOTHERAPY RENAL CELL CARCINOMA

Contacts and locations

Locations

Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University
RECRUITING

Nanjing, Jiangsu, 210000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.